Related Experiment Video

Updated: Jun 16, 2025

Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer
04:04

Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer

Published on: February 12, 2017

10.4K

Letter Re: Correlation between irAEs and survival outcomes in patients with ES-SCLC treated with first-line

Taha Koray Sahin1, Deniz Can Guven1

  • 1Hacettepe University Oncology Hospital, Ankara, Turkiye.

European Journal of Cancer (Oxford, England : 1990)
|June 13, 2025
PubMed
Abstract

No abstract available in PubMed .

Keywords:
Immune check point inhibitorsImmune-related adverse eventsImmunotherapySmall-cell lung cancer

More Related Videos

Predictive Immune Modeling of Solid Tumors
08:50

Predictive Immune Modeling of Solid Tumors

Published on: February 25, 2020

6.9K
Detection of a Circulating MicroRNA Custom Panel in Patients with Metastatic Colorectal Cancer
08:12

Detection of a Circulating MicroRNA Custom Panel in Patients with Metastatic Colorectal Cancer

Published on: March 14, 2019

5.4K

Related Experiment Videos

Last Updated: Jun 16, 2025

Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer
04:04

Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer

Published on: February 12, 2017

10.4K
Predictive Immune Modeling of Solid Tumors
08:50

Predictive Immune Modeling of Solid Tumors

Published on: February 25, 2020

6.9K
Detection of a Circulating MicroRNA Custom Panel in Patients with Metastatic Colorectal Cancer
08:12

Detection of a Circulating MicroRNA Custom Panel in Patients with Metastatic Colorectal Cancer

Published on: March 14, 2019

5.4K

Related Concept Videos

Cancer Survival Analysis01:21

Cancer Survival Analysis

334
Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...
334
Comparing the Survival Analysis of Two or More Groups01:20

Comparing the Survival Analysis of Two or More Groups

162
Survival analysis is a cornerstone of medical research, used to evaluate the time until an event of interest occurs, such as death, disease recurrence, or recovery. Unlike standard statistical methods, survival analysis is particularly adept at handling censored data—instances where the event has not occurred for some participants by the end of the study or remains unobserved. To address these unique challenges, specialized techniques like the Kaplan-Meier estimator, log-rank test, and...
162

Articles linked to this work by shared authors, journal, and citation graph.

Clinical Characteristics and Survival Outcomes of a Clinically Defined Treatment-Emergent Neuroendocrine/Aggressive-Variant Prostate Cancer Phenotype: A Retrospective Study.

Medicina (Kaunas, Lithuania)·2026

Radiological Response to Capecitabine and Temozolomide in an Elderly Patient with Metastatic Leiomyosarcoma: A Case Report.

Journal of clinical medicine·2026

Demographic Characteristics, Clinical Features, and Treatment Patterns of Classic and AIDS-Related Kaposi Sarcoma: A Multicenter Real-World Study from Turkey.

Medicina (Kaunas, Lithuania)·2026

Surgical Management of Early-Onset Breast Cancer Among Young BRCA1 and BRCA2 Carriers.

JAMA network open·2026

Consolidative thoracic radiotherapy following first-line chemo-immunotherapy in extensive-stage small-cell lung cancer: A systematic review and meta-analysis.

Therapeutic advances in medical oncology·2026

Chemotherapy type and survival in young BRCA1/2 carriers with HER2-negative early breast cancer.

European journal of cancer (Oxford, England : 1990)·2026

Refining neoplasm risk in DICER1-related tumor predisposition.

European journal of cancer (Oxford, England : 1990)·2026

Towards a more proportionate EU framework for low-intervention clinical trials: Lessons from the UK and Switzerland.

European journal of cancer (Oxford, England : 1990)·2026

Recent trends in childhood, teenage and young adult cancer incidence in England (2001-2020).

European journal of cancer (Oxford, England : 1990)·2026

A randomized trial to evaluate the effect of epigallocatechin gallate (EGCG) on EBV reactivation in patients with nasopharyngeal carcinoma in remission -the TCOG T2312 study.

European journal of cancer (Oxford, England : 1990)·2026

Molecular characteristics and clinical outcomes of ERBB2-activating mutation-positive non-small cell lung cancer: A Japanese nationwide real-world cohort.

European journal of cancer (Oxford, England : 1990)·2026

Timing of first-line palliative systemic therapy in metastatic esophagogastric adenocarcinoma: A population-based analysis & target trial emulation.

European journal of cancer (Oxford, England : 1990)·2026

Genetic background shapes the naïve IgM B cell receptor repertoire in mice.

Frontiers in immunology·2026

Genetically Predicted IgG N-Glycosylation Traits and Risk of Pre-Eclampsia or Eclampsia: A Two-Sample and Multivariable Mendelian Randomization Study.

International journal of women's health·2026

Isolated A1-domain F8 large deletions are associated with favorable immune tolerance induction outcomes in children with severe hemophilia A.

Research and practice in thrombosis and haemostasis·2026

Immune checkpoint inhibitor-induced myocarditis with myositis and/or myasthenia gravis overlap syndrome: A case series.

Experimental and therapeutic medicine·2026

Real-time pharmacovigilance and cardiac risk communication during the COVID-19 vaccination campaign in Israel.

EXCLI journal·2026

Mesenchymal stem cells: a potential therapeutic strategy for IgA nephropathy.

Frontiers in pharmacology·2026
See all related articles
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies
Jove
Visualize
Contact Us